View Older Stories View More Recent Stories

Jan 7, 2022 06:46AM Albireo Pharma (ALBO) Bylvay Launch Faster Than Anticipated, Raising Estimates - H.C. Wainwright

Jan 7, 2022 06:37AM Avalo Therapuetics (AVTX) is Attractive Among Small-Caps, Optimism for Both Upcoming Readouts Given Prior Proof-of-Concept - Oppenheimer

Jan 7, 2022 06:31AM Kinnate Biopharma (KNTE) Attractive into Two Separate Upcoming Catalysts - Stifel

Jan 7, 2022 06:25AM Intellia Therapeutics (NTLA) Has Major Opportunities in 2022 with With Multiple High Impact Data Readouts - Truist

Jan 7, 2022 06:22AM Neurocrine Biosciences (NBIX) Stock to Downtick in Light of Sales Miss, Needs More Growth Visibility - Needham

Jan 7, 2022 06:15AM Sarepta Therapeutics' (SRPT) Upcoming Readout May Support Approval, Bring 10-20% Upside to Stock - Raymond James

Jan 6, 2022 01:26PM Trevi Therapeutics' (TRVI) Upcoming PRISM Trial Readout is the Most Important Value-Driver - Needham

Jan 5, 2022 10:27AM Intellia Therapeutics' (NTLA) Management Unlocking Potential, Partnership Suggests Strength - Stifel

Jan 5, 2022 09:58AM Ultragenyx Pharma's (RARE) Update Sets Positive Tone, Prospects Are Optimistic - Stifel

Jan 5, 2022 09:33AM Bicycle Therapeutics Plc (BCYC) Data Continues to Trend in the Right Direction - Needham

Jan 4, 2022 11:11AM Aytu BioScience's (AYTU) Experienced CFO Hire is a Positive For the Company - Cantor Fitzgerald

Jan 4, 2022 10:37AM AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel

Jan 3, 2022 05:39AM Yearly Drug Price Changes by Biogen (BIIB), Gilead (GILD), Regeneron (REGN) and Vertex (VRTX) - Truist

Dec 30, 2021 11:15AM Immunovant's (IMVT) Opportunity is Sizable, But May Take Longer to Realize the Potential - Truist

Dec 30, 2021 11:02AM No Negative in Madrigal Pharma's (MDGL) Topline Data Delay - H. C. Wainwright

Dec 30, 2021 10:00AM Omicron May Boost ProPhase Labs (PRPH), But Long-Term Concerns Remain - Dawson James

Dec 29, 2021 05:01PM Biogen (BIIB) Could be Valued at $42B Cash in Samsung Deal, Here Are Key Questions According to Truist Securities

Dec 29, 2021 08:15AM XBI Will Rebound, COVID Will Ease, Gene Therapy Approvals to Triple, Focus on NASH to Return - William Blair Biotech Predictions for 2022

Dec 28, 2021 06:02AM Alnylam Pharma (ALNY) Skepticism is Unwarranted, Weakness is a Major Buying Opportunity - Oppenheimer

Dec 27, 2021 11:35AM BridgeBio Pharma's (BBIO) acoramidis Removed From Model, All Focus on infigratinib - Raymond James

Dec 22, 2021 02:58PM Mereo's (MREO) Alvelestat's Excellent Tolerability and Ease of Administration Highlight Potential in Multiple Indications - Needham

Dec 22, 2021 06:18AM Allakos' (ALLK) Data is Disappointing, Future of lirentelimab is Uncertain - William Blair

Dec 22, 2021 06:09AM Zogenix (ZGNX) is a Top Pick, Upcoming Catalysts Will Drive Sales, Current Valuation is an Opportunity - Needham

Dec 22, 2021 05:59AM Jaguar Health's (JAGX) Recent Approval Underscores that Portfolio and Execution are Underappreciated - Cantor Fitzgerald

Dec 21, 2021 01:01PM PhaseBio's (PHAS) Halt of PB1046 is a Necessary Step to Focus on Bentracimab, Reiterate Buy - Needham

Dec 21, 2021 11:58AM Clearside's (CLSD) CLS-AX Safety Data is a Positive, but Therapeutics Potential Remains Unclear till Phase 2 - Needham

Dec 21, 2021 11:44AM Aridis' (ARDS) Omicron Data is Positive, Reiterates Belief that Pipeline is Undervalued - Cantor Fitzgerald

Dec 21, 2021 09:11AM I-Mab's (IMAB) Leadership Changes Position for Increased Commercial Focus - Needham

Dec 21, 2021 05:37AM Acadia's (ACAD) sNDA Resubmission is Risky Strategy, Outlook for Nuplazid in ADP Remains Highly Uncertain - Raymond James

Dec 20, 2021 10:56AM bluebird bio (BLUE) Clinical Hold Raises Even More Safety Questions, Outlook is Cautious - BMO Capital Markets

Dec 20, 2021 08:57AM CRISPR's (CRSP) Management Shuffling is Necessary, Shares Remain Highly Attractive - Truist

Dec 20, 2021 08:50AM Biogen's (BIIB) Price Reduction May Increase Aduhelm Uptake, but NCD Coverage Decision Remains Key - Analyst

Dec 20, 2021 06:07AM argenx's (ARGX) Vyvgart Approval is a Relief, Broad Label and Competitive Pricing Set Up for Great 2022 and Beyond - Truist

Dec 17, 2021 03:45PM Oxbryta Approval and Positive Opinion Bode Well for Sales, Each Are Meaningful Opportunities for Global Blood Therapeutics (GBT) - Stifel

Dec 17, 2021 12:58PM Passage Bio (PASG) GM1 Safety/Efficacy Data Validate Approach, Positive for Rest of Pipeline - Raymond James

Dec 17, 2021 08:41AM Biogen (BIIB) Aduhelm's EU Opportunity is Not Even in Model, All Focus on Lecanemab - Truist Securities

Dec 17, 2021 07:59AM Biogen (BIIB) and Aduhelm Remain Underappreciated Despite Negative EMA CHMP Opinion - Needham

Dec 17, 2021 06:14AM Jazz Pharmaceuticals (JAZZ) Remains Undervalued, but Epidiolex Sales Growth Rate Will Continue Slowing Down - Needham

Dec 16, 2021 11:00AM AcelRx Pharma's (ACRX) New Study Shows Multiple Advantages of DSUVIA Over Conventional Pain Management - H.C.Wainwright

Dec 16, 2021 07:50AM Pear Therapeutics (PEAR) is PDT Pioneer, Challenges Exist, but Poised for Long-Term Success – Analyst

Dec 13, 2021 09:59AM Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst

Dec 13, 2021 09:30AM Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst

Dec 9, 2021 08:44AM uniQure's (QURE) HOPE B Data In-Line With Expectations, Potential Peak Royalties of $485M - Analyst

Dec 7, 2021 06:14AM Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst

Dec 2, 2021 07:12AM Harmony’s (HRMY) Phase 3 for pitolisant in IH is Positive Development, Opens Door for Label Expansion - Analyst

Dec 1, 2021 08:49AM Vertex’s (VRTX) VX-147 Data Well Above Expectations, Potential $1B Opportunity - Analyst

Dec 1, 2021 08:38AM BioXcel's (BTAI) Delay May Signal Broader Label and Offer Additional Upside - Analyst

Nov 30, 2021 07:44AM MEI Pharma’s (MEIP) zandelisib Has Best-in-Class Potential, Poised to Dominate the Space - Analyst

Nov 29, 2021 08:49AM Hertz (HTZ) Intends to Repurchase Up to a Third of Free-Floating Shares

Nov 22, 2021 07:28AM Amgen (AMGN) Headed Sub-$200, Multiple 2022 Headwinds – Analyst

View More Recent Stories View Older Stories